MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 6, 2008, Pages 1439-1444

  Mihaljevic Peles, Alma ^a   Bozina, Nada ^a   Sagud, Marina ^a   Rojnic Kuzman, Martina ^a   Lovric, Mila ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Major depression; MDR1; P glycoprotein; Paroxetine; Treatment outcome

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DIAZEPAM; DOXEPIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PAROXETINE; PHENYTOIN; TRIMIPRAMINE; VENLAFAXINE;

ABCB1 GENE; ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; C3435T GENE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ETHNIC DIFFERENCE; EXON; FEMALE; G2677T GENE; GENE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAMILTON SCALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MDR1 GENE; OPEN STUDY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STRUCTURED INTERVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ALLELES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; FALSE POSITIVE REACTIONS; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MUTATION; P-GLYCOPROTEIN; PAROXETINE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES;

EID: 47749090870     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.03.018     Document Type: Article

References (67)

1. Ameyaw M.M., Regateiro F., Li T., Liu X., Tariq M., Mobarek A., et al. MDR1 pharmacogenetics: frequency of the C34435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11 (2001) 217-221
2. Basic S., Hajnsek S., Bozina N., Filipcic I., Sporis D., Mislov D., et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 6 (2008) Mar [Electronic publication ahead of print]
3. Bozina N., Rojnic Kuzman M., Medved V., Jovanovic N., Sertic J., and Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 42 (2008) 89-97
4. Buchner A., Erdfelder E., and Faul F. How to Use G*Power (1997). http://www.psycho.uni-duesseldorf.de/aap/projects/gpower/how_to_use_gpower.ht [WWW document]. URL http://www.psycho.uni-duesseldorf.de/aap/projects/gpower/how_to_use_gpower.ht
5. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphism in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69 (2001) 169-174
6. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., and Melamed MR Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86 (1989) 695-698
7. De Luca V., Mundo E., Trakalo J., Wong G.W., and Kennedy J.L. Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania. Pharmacogenomics J 3 (2003) 297-299
8. Dombrowski S.M., Desai S.Y., Marroani M., Cucullo L., Goodrich K., Bingaman W., et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42 (2001) 1501-1506
9. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25 (2003) 115-121
10. Eichelbaum M., Fromm M.F., and Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 26 (2004) 180-185
11. El Ela A.A., Hartter S., Schmitt U., Hiemke C., Spahn-Langguth H., and Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56 (2004) 967-975
12. Elmore J.G., Moceri V.M., Carter D., and Larson E.B. Breast carcinoma tumor characteristic in black and white women. Cancer 83 (1998) 2509-2515
13. Excoffier L., Laval G., and Schneider S. Arlequin ver. 3.01: An Integrated Software Package for Population Genetic Data Analysis (2006), University of Bern, Switzerland
14. Farrell R.J., Murphy A., Long A., Donnelly S., Cherikuri A., O'Toole D., et al. High multidrug resistance (P-glycoprotein 170) expresion in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118 (2000) 279-288
15. From M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25 (2004) 423-429
16. Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54 (2002) 1295-1310
17. Funae Y., Kishimoto W., Cho T., Niwa T., and Hiroi T. CYP2D in the Brain. Drug Metab Pharmacokinet 18 (2003) 337-349
18. Furuno T., Landi M.T., Ceroni M., Caporaso N., Bernucci I., Nappi G., et al. MDR1 polymorphism and Parkinson's disease. Drug Metab Rev 33 (2001) 129
19. Giessmann T., May K., Modess C., Wegner D., Hecker U., Zschiesche M., et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 76 (2004) 192-200
20. Grauer M.T., and Uhr M. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after 10-day administration of amitriptyline. J Psychopharmacol 18 (2004) 66-74
21. Guo S.W., and Thompson E.A. Performing the exact test of Hardy-Weinberg proportions for multiple alleles. Biometrics 48 (1992) 361-372
22. Haenisch S., Zimmermann U., Dazert E., Wruck C.J., Dazert P., Siegmund S., et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 7 (2007) 56-65
23. Hamilton M. A rating scale for depression. J Neurosurg Psychiatry 23 (1960) 56-62
24. Hedlund E., Gustafsson J.A., and Warner M. Cytochrome P450 in the brain. Curr Drug Metab 2 (2001) 245-263
25. Hitzl M., Drescher S., van der Kuip H., Schaffeler E., Fischer J., Schwab M., et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11 (2001) 293-298
26. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug- resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 (2000) 3473-3478
27. Ho G.T., Nimmo E.R., Tenesa A., Fennell J., Drummond H., Mowat C., et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behaviour in ulcerative colitis. Gastroenterology 128 (2005) 288-296
28. Ieiri I., Hiroshi T., and Otsubo K. The MDR1(ABCB1) Gene Polymorphism and its Clinical Implications. Clin Pharmacokinet 43 (2004) 553-576
29. Kakumoto M., Takara K., Sakaeda T., Taningawara Y., Kita T., and Okumura K. MDR1-mediatet interaction of digoxin with antiarrhythmic or antianginal drugs. Biol Pharm Bull 25 (2002) 1604-1607
30. Kato M., Fukuda T., Serretti A., Wakeno M., Okugawa G., Ikenaga Y., et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuro-psychopharmacol Biol Psychiatry 15 32 (2008) 398-404
31. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70 (2001) 189-199
32. Kim D.W., Kim M., Lee S.K., Kang R., and Lee S.Y. Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 15 (2006) 344-347
33. Kwan P., and Brodie M.J. Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy. Epilepsia 46 (2005) 224-235
34. Laika B., Leucht S., and Steimer W. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem 52 (2006) 893-895
35. Lee G., and Bendayan R. Functional expression and localization of P-glicoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm Res 21 (2004) 1313-1330
36. Lin J.H., and Yamazaki M. Role of p-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42 (2003) 59-98
37. Ling V. Multidrug resistance: molecular mechanism and clinical relevance. Cancer Chemother Pharmacol 40 Suppl (1977) S3-S8
38. Loscher W., and Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 301 (2002) 7-14
39. Meines L.W., Antonetti D.A., Wolpert E.B., and Smith C.D. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazepine by bovine retinal endothelial cells. Neuropharmacol 49 (2005) 610-617
40. Nakamura T., Sakaeda T., Horinouchi M., Tamura T., Aoyama N., Schirakawa T., et al. Effect of the mutation (C3435T) et exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71 (2002) 297-303
41. Okamura N., Hirai M., Tanigawara Y., Tanaka K., Yasuhara M., Ueda K., et al. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 266 (1993) 1614-1619
42. Pauli-Magnus C., Feiner J., Brett C., Lin E., and Kroetz D.L. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 74 (2003) 487-498
43. Prior T.I., and Baker G.B. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28 (2003) 99-112
44. Qian W., Homma M., Itagaki F., Tachikiwa H., Kawanishi Y., Mizukami K., et al. MDR1 Gene Polymorphism in Japanese Patients with Schizophrenia and Mood Disorders Including Depression. Biol Pharm Bull 29 (2006) 2446-2450
45. Roberts R.L., Joyce P.R., Mulder R.T., Begg E.J., and Kennedy M.A. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2 (2002) 191-196
46. Sakaeda T. MDR1 genotype-related Pharmacokinetics: Fact or Fiction?. Drug Metab Pharmacokinet 20 (2005) 391-414
47. Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N., Sakai T., et al. MDR1 genotype related pharmacokinetics of digoxin after oral administration in healthy Japanese subjects. Pharm Res 18 (2001) 1400-1404
48. Siddiqui A., Kerb R., Weale M.E., Brinkmann U., Smith A., Goldstein D.B., et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348 (2003) 1442-1448
49. Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder E., Sperker B., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72 (2002) 572-583
50. Siegsmund M., Brinkmann U., Schaffeler E., Weirich G., Schwab M., Eichelbaum M., et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumours. J Am Soc Nephrol 13 (2002) 1847-1854
51. Sills G.J., Mohanraj R., Butler E., McCrindle S., Collier L., Wilson E.A., et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46 (2005) 643-647
52. Silverman J.A. P-Glycoprotein. In: Rene' L. (Ed). Metabolic Drug Interactions (2000), Lippincott-Raven Press, Philadelphia 83-88
53. Slatkin M., and Excoffier L. Testing for linkage disequilibrium in genotypic data using the EM algorithm. Heredity 76 (1996) 377-383
54. Takao T., Tachikawa H., Kawanishi Y., Katano Y., Sen B., Homma M., et al. Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene. Psychiatr Genet 16 (2006) 47-48
55. Tang K., Ngoi S.M., Gwee P.C., Chua J.M., Lee E.J., Chong S.S., et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12 (2002) 437-450
56. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84 (1987) 7735-7738
57. Thompson J.S., Koszdin K., and Bernadsrs C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anaesthesiology 92 (2000) 1392-1399
58. Thuerauf N., and Fromm M.F. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci 256 (2006) 281-286
59. Uhr M., Grauer M.T., and Holsboer F. Differential enhancement of antidepressant penetration into the brain mice with abcb1bab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54 (2003) 840-846
60. Uhr M., Grauer M.T., Yassouridis A., and Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res 41 (2007) 179-188
61. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57 (2008) 203-209
62. Wang J.S., Zhu H.J., Markowitz J.S., Donovan J.L., and Devane C.L. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 187 (2006) 415-423
63. Weiss J., Sven-Maria G.D., Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash K., and Haefeli W.E. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305 (2003) 197-204
64. Weiss J., Kerpen C.J., Lindenmaier H., Dorman S.M., and Haefeli W.E. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 307 (2003) 262-267
65. Westphal K., Weinbrenner A., Zschiesche M., Franke G., Knoke M., Oertel R., et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68 (2000) 345-355
66. Yasui-Furukori N., and Kaneko S. Digitalis intoxication induced by paroxetine co-administration. Lancet 367 (2006) 788
67. Yasui-Furukori N., Saito M., Niioka T., Inoue Y., Sato Y., and Kaneko S. Effect of Itraconazole on Pharmacokinetics of Paroxetine: The role of Gut Transporters. Ther Drug Monit 29 (2007) 45-48